To The Moon

With the continuous advancement of AI technology, more innovative medical applications will inevitably emerge in the future. $Recursion Pharmaceuticals, Inc.(RXRX)$ partnered with chipmaker $NVIDIA Corp(NVDA)$ in 2023 to conduct AI-led drug development, and the company's stock surged after the announcement.

On Wednesday, $Moderna, Inc.(MRNA)$ , the developer of the COVID-19 vaccine, announced a partnership with OpenAI to deploy the AI company's ChatGPT Enterprise in its business to accelerate drug development.

According to the collaboration agreement, approximately 3,000 Moderna employees will have access to ChatGPT Enterprise, built on OpenAI's cutting-edge language model GPT-4, by the end of this week. The financial terms of the deal have not been disclosed.

The two companies began collaborating in early 2023 and launched a customized version of ChatGPT called mChat, which has been used by over 80% of Moderna's employees since its launch.

The companies jointly stated:

This initial collaboration has successfully accelerated the development of an AI culture, comprehensively driving the deployment of ChatGPT Enterprise and its enhanced features such as advanced micro-level analysis, image generation, and GPTs.

Stéphane Bancel, CEO of Moderna, said,

Moderna has ambitious plans to launch multiple products in the next few years, and collaborations with companies like OpenAI are crucial for us to scale up and maximize our impact on patients.

Sam Altman, CEO of OpenAI, added,

People always talk about how AI will someday cure diseases, and I think this is a very meaningful first step.

Other stocks worth keeping an eye on that could capitalize on the AI+pharma opportunity include $Schrodinger Inc.(SDGR)$ $Absci Corporation.(ABSI)$ and $Exscientia plc(EXAI)$.